{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:50:01Z","timestamp":1783403401427,"version":"3.54.6"},"reference-count":52,"publisher":"Informa UK Limited","issue":"1","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Medical Economics"],"published-print":{"date-parts":[[2025,12,31]]},"DOI":"10.1080\/13696998.2025.2579407","type":"journal-article","created":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T14:15:11Z","timestamp":1761315311000},"page":"1933-1954","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":2,"title":["Nirmatrelvir\/ritonavir treatment for COVID-19: an economic value systematic literature review"],"prefix":"10.1080","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7515-8548","authenticated-orcid":false,"given":"Tendai","family":"Mugwagwa","sequence":"first","affiliation":[{"name":"Global Access and Value, Pfizer Ltd","place":["Tadworth, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3372-2996","authenticated-orcid":false,"given":"Jos\u00e9","family":"Marcano Belisario","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Manchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5251-2321","authenticated-orcid":false,"given":"Louise","family":"Hartley","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Manchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3603-1736","authenticated-orcid":false,"given":"Nguyen Thi Nhan","family":"Phan","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Manchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"e_1_3_7_2_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-09783-9"},{"key":"e_1_3_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05522-2"},{"key":"e_1_3_7_4_1","unstructured":"Statista [Internet]. Incidence of coronavirus (COVID-19) cases in Europe as of January 13 2023 by country. 2024. https:\/\/www.statista.com\/statistics\/1110187\/coronavirus-incidence-europe-by-country\/"},{"key":"e_1_3_7_5_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000004213"},{"key":"e_1_3_7_6_1","unstructured":"Treasury H. 2023 HM Treasury COVID-19 Cost Tracker update. 2023. https:\/\/assets.publishing.service.gov.uk\/media\/64b8fcc9ef537100147aef44\/2023_HMT_COVD-19_Cost_Tracker_update.pdf"},{"key":"e_1_3_7_7_1","unstructured":"International Monetary Fund. World economic outlook briefing transcript. 2022. https:\/\/www.imf.org\/en\/News\/Articles\/2022\/01\/25\/tr01252022-world-economic-outlook-briefing"},{"key":"e_1_3_7_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-022-00154-z"},{"key":"e_1_3_7_9_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1130539"},{"key":"e_1_3_7_10_1","unstructured":"Centers for Disease Control and Prevention. Underlying conditions and the higher risk for severe COVID-19. 2025. https:\/\/www.cdc.gov\/covid\/hcp\/clinical-care\/underlying-conditions.html"},{"key":"e_1_3_7_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12985-023-01973-9"},{"key":"e_1_3_7_12_1","unstructured":"European Medicines Agency. COVID-19 medicines. 2025. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/public-health-threats\/coronavirus-disease-covid-19\/covid-19-medicines"},{"key":"e_1_3_7_13_1","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) | Drugs. 2023. https:\/\/www.fda.gov\/drugs\/emergency-preparedness-drugs\/coronavirus-covid-19-drugs"},{"key":"e_1_3_7_14_1","unstructured":"European Medicines Agency. COVID-19: EMA recommends conditional marketing authorisation for Paxlovid. 2022. https:\/\/www.ema.europa.eu\/en\/news\/covid-19-ema-recommends-conditional-marketing-authorisation-paxlovid#:\u223c:text=Update%3A%20Paxlovid%20is%20now%20authorised%20across%20the%20EU. by%20the%20European%20Commission%20on%2028%20January%202022"},{"key":"e_1_3_7_15_1","unstructured":"European Medicines Agency. Paxlovid. 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/paxlovid#authorisation-details"},{"key":"e_1_3_7_16_1","unstructured":"US Food and Drug Administration. FDA approves first oral antiviral for treatment of COVID-19 in adults. 2023. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-oral-antiviral-treatment-covid-19-adults"},{"key":"e_1_3_7_17_1","unstructured":"US Food and Drug Administration. Coronavirus (COVID-19) update: FDA authorizes first oral antiviral for treatment of COVID-19. 2021. https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19"},{"key":"e_1_3_7_18_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciac443"},{"key":"e_1_3_7_19_1","doi-asserted-by":"publisher","DOI":"10.3855\/jidc.19202"},{"key":"e_1_3_7_20_1","unstructured":"Pfizer. Pfizer shares in vitro efficacy of novel COVID-19 oral treatment against omicron variant. 2022. https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-shares-vitro-efficacy-novel-covid-19-oral-treatment"},{"key":"e_1_3_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(23)00118-4"},{"key":"e_1_3_7_22_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid3002.230835"},{"key":"e_1_3_7_23_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.313.7052.275"},{"key":"e_1_3_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2024.03.632"},{"key":"e_1_3_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.11.003"},{"key":"e_1_3_7_26_1","unstructured":"Institute for Clinical and Economic Review. Special assessment of outpatient treatments for COVID-19. 2022. https:\/\/icer.org\/wp-content\/uploads\/2021\/08\/ICER_COVID_19_Final_Evidence_Report_051022.pdf"},{"key":"e_1_3_7_27_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.22-0106"},{"key":"e_1_3_7_28_1","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-2191067\/v1"},{"key":"e_1_3_7_29_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2023.29.12.1290"},{"key":"e_1_3_7_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac637"},{"key":"e_1_3_7_31_1","doi-asserted-by":"publisher","DOI":"10.3310\/NAFW3527"},{"key":"e_1_3_7_32_1","unstructured":"National Institute for Health and Care Excellence. TA878. Nirmatrelvir plus ritonavir sotrovimab and tocilizumab for treating COVID-19. 2023. https:\/\/www.nice.org.uk\/guidance\/ta878"},{"key":"e_1_3_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vhri.2023.09.005"},{"key":"e_1_3_7_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2023.09.025"},{"key":"e_1_3_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2024.02.001"},{"key":"e_1_3_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanwpc.2022.100602"},{"key":"e_1_3_7_37_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1174879"},{"key":"e_1_3_7_38_1","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2022034"},{"key":"e_1_3_7_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.1800"},{"key":"e_1_3_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.603"},{"key":"e_1_3_7_41_1","unstructured":"CDA-AMC Canada\u2019s Drug Agency. Nirmatrelvir-ritonavir (Paxlovid): CADTH reimbursement recommendation: indication for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing and who are at high risk for progression to severe COVID-19 including hospitalization or death. 2024."},{"key":"e_1_3_7_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40801-024-00427-0"},{"key":"e_1_3_7_43_1","unstructured":"Birnie E Vergouwe M Appelman B et al. EO441 Cost-effectiveness analysis of nirmatrelvir\/ritonavir for high-risk individuals with COVID-19: a modelling study. 2025. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2950590924000131?ref=pdf_download&fr=RR-2&rr=976d6d9acce81392"},{"key":"e_1_3_7_44_1","unstructured":"Edoka I Drake T Baker P et al. A cost-effectiveness analysis of Molnupiravir and Paxlovid in three African countries. medRxiv. 2023. http:\/\/medrxiv.org\/content\/early\/2023\/07\/05\/2023.07.05.23292205.abstract"},{"key":"e_1_3_7_45_1","unstructured":"CDA-AMC Canada\u2019s Drug Agency. Nirmatrelvir\/ritonavir (Paxlovid). Canada\u2019s Drug Agency reimbursement review. 2024. https:\/\/www.cda-amc.ca\/sites\/default\/files\/DRR\/2024\/SR0808_Combine_Report.pdf"},{"key":"e_1_3_7_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2023.09.909"},{"key":"e_1_3_7_47_1","unstructured":"ClinicalTrials.gov NCT04960202. EPIC-HR: study of oral PF-07321332\/\u200britonavir compared with placebo in nonhospitalized high risk adults with COVID-19. 2023. https:\/\/clinicaltrials.gov\/study\/NCT04960202"},{"key":"e_1_3_7_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-022-01168-0"},{"key":"e_1_3_7_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01654-5"},{"key":"e_1_3_7_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2010.10.029"},{"key":"e_1_3_7_51_1","unstructured":"Cascella M Rajnik M Aleem A et al. Features evaluation and treatment of Coronavirus (COVID-19). 2023. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK554776\/#:\u223c:text=Data%20from%20the%20National%20Vital risk%20increases%20to%2060%20times"},{"key":"e_1_3_7_52_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2023.0743"},{"key":"e_1_3_7_53_1","unstructured":"Carlson J Foos V Kasle A et al. P0340 Cost-effectiveness of oral nirmatrelvir\/ritonavir in patients at high risk for progression to severe COVID-19 in the United States. 2025. https:\/\/www.sciencedirect.com\/science\/article\/pii\/S2950590924000131?ref=pdf_download&fr=RR-2&rr=976d6d9acce81392"}],"container-title":["Journal of Medical Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13696998.2025.2579407","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:49:19Z","timestamp":1766400559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13696998.2025.2579407"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":52,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,12,31]]}},"alternative-id":["10.1080\/13696998.2025.2579407"],"URL":"https:\/\/doi.org\/10.1080\/13696998.2025.2579407","relation":{},"ISSN":["1369-6998","1941-837X"],"issn-type":[{"value":"1369-6998","type":"print"},{"value":"1941-837X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijme20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-07-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}